La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Bowman Consulting Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Bowman Consulting Group..

Bowman Consulting Group (NASDAQ:BWMN) Azioni, Catena delle Opzioni

Bowman Consulting Group

Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape, and Architecture/Planning.

Bowman Consulting Group Ltd. - Common Stock

Bowman Consulting Group Ltd

OTR Global downgrades Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Mixed to Negative.

News

Downgrades

Analyst Ratings

PANW

OTR Global Downgrades Palo Alto Networks to Negative

Schwab Asset Management&#xAE;, the asset management arm of The Charles Schwab Corporation, today announced the launch of the Schwab Mortgage-Backed Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBS#NYSE">SMBS</a>). The first day of trading is expected to be on or about November 19.
With an expense ratio of 0.03%, the Schwab Mortgage-Backed Securities ETF is priced in line with the lowest-priced peer ETFs based on the U.S. Mortgage Lipper category1. The ETF will provide simple access to investment-grade mortgage-backed securities issued and/or guaranteed by U.S. government agencies. It is designed to serve as part of a diversified portfolio.

ETFs

SCHW

SMBS

Schwab Asset Management To Launch The Schwab Mortgage-Backed Securities ETF "SMBS" On Or About November 19

Buybacks

STGW

Stagwell Reveals $125M Increase In Stock Repurchase Program

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Hold.

Reiteration

GILD

Needham Reiterates Hold on Gilead Sciences

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587386a45064ed0001b4b61b/lauren-lieberman">Barclays analyst Lauren Lieberman</a> downgraded the rating for Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) from Equal-Weight to Underweight and lowered the price target from $8 to $7. Coty shares closed at $7.43 on Wednesday. <a href="https://www.benzinga.com/quote/COTY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sean Milligan downgraded Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Hold to Underperform and cut the price target from $93 to $61. Enphase Energy shares closed at $74.81 on Wednesday. <a href="https://www.benzinga.com/quote/ENPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Laura Champine downgraded the rating for Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) from Buy to Hold and lowered the price target from $150 to $110. Crocs shares closed at $102.74 on Wednesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Toni Sacconaghi downgraded Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Outperform to Market Perform and announced a price target of $11. Ford shares closed at $11.19 on Wednesday. <a href="https://www.benzinga.com/quote/F/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59009b5a0bd9910001e5f2aa/bradley-thomas">Keybanc analyst Bradley Thomas </a>downgraded the rating for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from Overweight to Sector Weight. Dollar Tree shares closed at $62.41 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Ford stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-1024x586.png" alt="" class="wp-image-635158" style="width:545px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

COTY

CROX

DLTR

ENPH

This Ford Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

NKT Photonics to deliver three innovative prototype optical subsystems to IonQ in 2025
NKT Photonics' advanced laser systems will be integrated into IonQ's upcoming data center-ready quantum systems
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leader in the quantum computing industry, announced today a partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nktphotonics.com%2F&amp;esheet=54148577&amp;newsitemid=20241107761716&amp;lan=en-US&amp;anchor=NKT+Photonics&amp;index=1&amp;md5=e2aeed3e06c83873b1e9149d1f342cf4">NKT Photonics</a>, a subsidiary of Hamamatsu Photonics, to procure next-generation laser systems for IonQ's trapped-ion quantum computers and networking equipment. The partnership involves NKT Photonics developing and delivering three prototype optical subsystems to IonQ in 2025, designed to support the commercialization of IonQ's data center-ready quantum computers – such as IonQ Tempo and future barium-based systems.

IONQ

IonQ Announces Partnership With NKT Photonics For Next-Generation Laser Systems To Power Future Quantum Computers

Guidance

Stagwell Reaffirms FY24 Guidance For Organic Net Revenue Growth Of 5% To 7%; Adjusted EBITDA Of $400M - $450M; Free Cash Flow Conversion Of ~50%

Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 65.35 percent increase over losses of $(1.27) per share from the same period last year.

Earnings

Earnings Beats

LPCN

Lipocine Q3 EPS $(0.44) Beats $(0.48) Estimate

FSTR

L.B. Foster Sees FY 2024 Net Sales $530M-$540M Vs $540.92M Est.

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $207 price target.

Price Target

JAZZ

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target

General

COEP

Coeptis Therapeutics Announces Phase 1 Data On DVX201 For COVID-19 Treatment Has Been Accepted For Publication in 'Molecular Therapy Methods and Clinical Development'

WK Kellogg Raises FY24 Adj. EBITDA Guidance; Sees FY24 Adj. EBITDA Growth Of 5%-6%

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.72) by 11.11 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $354.62 million which beat the analyst consensus estimate of $225.00 thousand by 157.51K percent. This is a 110.90K percent increase over sales of $319.47 thousand the same period last year.

APRE

Aprea Therapeutics Q3 EPS $(0.64) Beats $(0.72) Estimate, Sales $354.62M Beat $225.00K Estimate

Endeavor Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>) reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.56 billion by 30.29 percent. This is a 51.12 percent increase over sales of $1.34 billion the same period last year.

Endeavor Q3 EPS From Cont. Ops $(0.44), Down From $(0.24) Last Year, Sales $2.03B, Up From $1.22B Prior Year

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) reported quarterly earnings of $3.27. The company reported quarterly sales of $137.50 million which missed the analyst consensus estimate of $141.78 million by 3.02 percent. This is a 5.40 percent decrease over sales of $145.34 million the same period last year.

Earnings Misses

L.B. Foster Q3 2024 GAAP EPS $3.27, Sales $137.50M Miss $141.78M Estimate

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.26 by 19.23 percent. The company reported quarterly sales of $689.000 million which beat the analyst consensus estimate of $674.044 million by 2.22 percent. This is a 0.43 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 2024 Adj. EPS $0.31 Beats $0.26 Estimate, Sales $689.000M Beat $674.044M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and maintains $100 price target.

KROS

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.42) by 23.81 percent. This is a 35.8 percent increase over losses of $(0.81) per share from the same period last year.

HLVX

HilleVax Q3 EPS $(0.52) Misses $(0.42) Estimate

Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 8.11 percent increase over losses of $(0.37) per share from the same period last year.

IMNN

Imunon Q3 2024 GAAP EPS $(0.34) Beats $(0.40) Estimate. Cash and Equivalents of $10.3M

Guidance
<ul>
<li>Q4 Consolidated Revenue expected to increase in the high-single digits</li>
<li>Full Year 2024 Consolidated Revenue expected to increase in the mid-single digits</li>
<li>Q4 Consolidated Adjusted EBITDA expected to be approximately $290 million, up approximately 39%</li>
<li>Full Year 2024 Consolidated Adjusted EBITDA expected to be approximately$750 million, up approximately 8%</li>
<li>Full Year 2025 Consolidated Revenue expected to be approximately flat in a non-political year</li>
<li>Full Year 2025 Consolidated Adjusted EBITDA3 expected to be approximately$770 million, up approximately 3% in a non-political year</li>
</ul>

IHRT

iHeartMedia Expects Q4 Revenue Growth Of High-Single Digits Vs $1.00B Est, Reiterated FY24 Revenue Growth Of Mid-Single Digits Vs $3.92B Est, FY25 Revenue Growth Of Approx Flat Vs $3.86B Est

Craig-Hallum analyst Aaron Spychalla maintained a Buy rating on Bowman Consulting Group (BWMN – Research Report) today. The company's shares closed...

Craig-Hallum Keeps Their Buy Rating on Bowman Consulting Group (BWMN)

Bowman Consulting gets contract from Virginia Department of Transportation

Bowman gets $1.2M contract for asset management, regulatory compliance tracking

In a report released today, Aaron Spychalla from Craig-Hallum maintained a Buy rating on Bowman Consulting Group (BWMN – Research Report). The comp...

Craig-Hallum Sticks to Their Buy Rating for Bowman Consulting Group (BWMN)

Conestoga Capital Advisors Q3 2024 Quarterly Commentary

Bowman Consulting Group (BWMN) Receives a Buy from Craig-Hallum

Bowman to acquire Exeltech Consulting

Bowman Consulting (BWMN) Group announced it has entered into a definitive purchase agreement to acquire Exeltech Consulting based in Lacey, Washing...

Bowman Consulting purchases Exeltech in 'immediately accretive' deal

The Company is raising its full year 2024 guidance for net service billing to be in the range of $376 to $386 million and reaffirming its guidance ...

Bowman Consulting backs FY24 adjusted EBITDA view $58M-$63M

Bowman Consulting Non-GAAP EPS of $0.30, revenue of $113.93M

AAON

ALTR

ANSS

AXON

BLFS

BWMN

CGNX

COCO

CPRT

CSGP

CSWI

CWST

DSGX

ERII

EXPO

FIVN

FOXF

FTNT

GWRE

HLMN

IDXX

IRMD

MAMA

MNESP

NOVT

OFLX

PCOR

PLMR

POOL

QTWO

RGEN

ROAD

SITE

SNPS

SPSC

TCYSF

TECH

THBRF

TKNO

TREX

TRNS

USPH

VCEL

VRSK

WLDN

Press Releases

Bowman Contracted for Comprehensive Roadway Improvement Project in Philadelphia

Bowman Contracted by Illinois Department of Transportation for I-55 Corridor Rehabilitation Project

Bowman Announces Planned Retirement of Michael Bruen

Bowman Contracted to Provide Support Services for Virginia Department of Transportation Design-Build Projects

Bowman Awarded Contract for Asset Management and Regulatory Compliance Tracking in Delaware Basin

Bowman Consulting Group Announces Dates for Third Quarter 2024 Earnings Release and Webcast

Bowman Publishes Initial Materiality Assessment

Bowman to Lead Program Management for The Aurora Highlands, the Largest Community Development in Denver Metro Area

Bowman to Acquire Exeltech, Expanding Bridge Design and Transportation Engineering

Bowman Announces Financial Results for Three and Nine Months Ended September 30, 2024

Argan

Ameresco

Concrete Pumping Holdings, Inc. - Common Stock

Concrete Pumping Holdings

Cadeler A/S American Depositary Share (each representing four (4) Ordinary Shares)

Comments

Bowman Consulting Group

Bowman Consulting Group (BWMN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO